{
    "clinical_study": {
        "@rank": "90558", 
        "arm_group": [
            {
                "arm_group_label": "PEG 4 litres split", 
                "arm_group_type": "Active Comparator", 
                "description": "Polyethylene glycol with electrolytes (PEG)"
            }, 
            {
                "arm_group_label": "Bisacodyl plus PEG-CS", 
                "arm_group_type": "Experimental", 
                "description": "Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study is intended to evaluate the effectiveness, tolerability, compliance, and\n      feasibility of the low volume bowel preparation, bisacodyl tablets followed by 2L\n      Polyethylene glycol (PEG) with citrate and simethicone (CS) given the same day of\n      colonoscopy, vs the standard 4L split PEG solution."
        }, 
        "brief_title": "Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Colonoscopy", 
        "detailed_description": {
            "textblock": "Eligible patients will be informed about the aims, procedures, benefits and possible risks\n      of the study prior to sign the informed consent form from day -30 to day-3. They will\n      provide medical history and undergo a physical examination. Patients will be evaluated by a\n      Physician other than the blind Endoscopist. The same responsible person will instruct the\n      patients about administration procedures in both oral and written form. The patients will be\n      assigned to receive one of the dosing schedule bowel preparation according to a computer\n      generated block-randomisation list. Patients will take the study treatment at home according\n      to the given instructions. Patients will return to the clinic for colonoscopy. The\n      colonoscopy will be performed by an Endoscopist who will be unaware of the bowel\n      dose-regimen preparation taken by the patient. Completed colonoscopic exam will be performed\n      with time recorded (intubation and withdrawal from ceacum). The unblind Investigator will\n      ask the patients about safety, tolerability, overall acceptance and compliance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Out-patients undergoing a complete colonoscopy\n\n          -  Patient written informed consent\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women or at a risk of becoming pregnant\n\n          -  Known or suspected gastrointestinal obstruction or perforation; toxic megacolon;\n             major colonic resection Known or suspected hypersensitivity to the active principle\n             and/or formulations' ingredients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "164", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685853", 
            "org_study_id": "IEO S570 510", 
            "secondary_id": "2010-022967-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bisacodyl plus PEG-CS", 
                "description": "the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime\nthe morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam", 
                "intervention_name": "Bisacodyl plus PEG-CS", 
                "intervention_type": "Drug", 
                "other_name": "LOVOLdyl plus LOVOLesse"
            }, 
            {
                "arm_group_label": "PEG 4 litres split", 
                "description": "the day before colonoscopy: 2 litres of PEG\nthe morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination", 
                "intervention_name": "PEG 4 litres split", 
                "intervention_type": "Drug", 
                "other_name": "SELG 1000"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bisacodyl"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 18, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Milan", 
                    "country": "Italy", 
                    "zip": "20141"
                }, 
                "name": "European Institute of Oncology"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study.", 
        "overall_official": {
            "affiliation": "European Institute of Oncology", 
            "last_name": "Cristiano Crosta, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation of the quality of bowel preparation according to the Ottawa Scale", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "20 min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685853"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of the mucosal visibility according to a 3 point scale (0-2)", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "20 min"
            }, 
            {
                "description": "Adenoma detection rate", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "20 min"
            }, 
            {
                "description": "Recording of all adverse events occurred during the study by patient questioning", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "rate of patients in the two groups who developed GI symptoms related to bowel preparation", 
                "measure": "Tolerability", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "willingness to repeat the preparation", 
                "measure": "Acceptability", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "rate of patient with intake of at least 75% of bowel preparation", 
                "measure": "Compliance", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "European Institute of Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Institute of Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}